Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:25:09 ON 08 JUN 2007

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:25:30 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Jun 2007 VOL 146 ISS 25
FILE LAST UPDATED: 7 Jun 2007 (20070607/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s SGLT activity?
           226 SGLT
            20 SGLTS
           235 SGLT
                 (SGLT OR SGLTS)
       2230907 ACTIVITY?
L1           4 SGLT ACTIVITY?
                 (SGLT(W)ACTIVITY?)

=> d ibib abs hitstr tot

L1   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2004:109791  CAPLUS
DOCUMENT NUMBER:         140:264951
TITLE:                   Atrial natriuretic peptide and endothelin-3 target
                         renal sodium-glucose cotransporter
AUTHOR(S):               Majowicz, M. P.; Gonzalez Bosc, L. V.; Albertoni
                         Borghese, M. F.; Delgado, M. F.; Ortiz, M. C.; Sterin
                         Speziale, N.; Vidal, N. A.
CORPORATE SOURCE:        Facultad de Farmacia y Bioquimica, Departamento de
                         Ciencias Biologicas, Biologia Celular e Histologia,
                         Universidad de Buenos Aires, Buenos Aires, 1113,
                         Argent.
SOURCE:                  Peptides (New York, NY, United States) (2003), 24(12),
```

1971-1976
CODEN: PPTDD5; ISSN: 0196-9781
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Atrial natriuretic peptide (ANP) and endothelin (ET) are endogenous vasoactive factors that exert potent diuretic and natriuretic actions. The authors have previously shown that ANP and ET-3 act through an NO pathway to inhibit the sodium-glucose cotransporter (SGLT) in the intestine. Here the authors address the role of ANP and ET-3 on SGLT activity in renal proximal tubules. In rat renal cortical brush border membranes (BBV), fluorescein isothiocianate (FITC) labeling revealed a specific 72 kDa peptide that exhibits increased FITC labeling in the presence of Na+ and D-glucose. Using α-14C-methylglucose active uptake, rat BBV were shown to possess SGLT activity with an affinity constant (K0.5 .apprx. 2.4 mM) that is consistent with the expression of the low-affinity, high-capacity SGLT2 isoform. SGLT2 activity in these prepns. is dramatically inhibited by ANP and ET-3. This inhibition is independent of changes in membrane lipids and is mimicked by the cGMP analog, 8-Br-cGMP, suggesting the involvement of cGMP/PKG pathways. These results are the first demonstration that both ANP and ET-3 inhibit rat cortical renal SGLT2 activity, and suggest a novel mechanism by which these vasoactive substances modulate hydro-saline balance at the proximal tubular nephron level.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:748998 CAPLUS
DOCUMENT NUMBER: 136:18115
TITLE: Aldosterone suppresses expression of an avian colonic sodium-glucose cotransporter
AUTHOR(S): Laverty, Gary; Bjarnadottir, Sesselja; Elbrond, Vibeke S.; Arnason, Sighvatur S.
CORPORATE SOURCE: Department of Biological Sciences, University of Delaware, Newark, DE, 19716, USA
SOURCE: American Journal of Physiology (2001), 281(4, Pt. 2), R1041-R1050
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Transport in the colon of the domestic fowl switches from sodium-linked hexose and amino acid cotransport on high-salt intake to amiloride-sensitive sodium channel expression on low-salt (LS) diets. The present expts. were designed to investigate the role of aldosterone in suppression of the colonic sodium-glucose luminal cotransporter (SGLT). LS-adapted hens were resalinated with or without simultaneous aldosterone treatment. Changes in the electrophysiol. responses and SGLT protein expression levels were examined at 1, 3, and 7 days of treatment. Serum aldosterone levels fell from .apprx.400 pM in LS-adapted hens to values below the detection limit (<44 pM) after 1 day of resalination. At the same time, glucose-stimulated short circuit current (ISC) increased from 20.9 to 56.3 μA/Cm2, whereas amiloride-sensitive ISC decreased from -68.9 μA/Cm2 on LS to + 0.6 μA/Cm2. Glucose-stimulated ISC increased further at 3 and 7 days of resalination, whereas amiloride-sensitive ISC remained suppressed. When resalinated birds were simultaneously treated with aldosterone, the LS pattern of high amiloride-sensitive ISC and low glucose-stimulated ISC was maintained. Immunoblotting results from the same tissues demonstrated that SGLT-like protein expression increased following resalination. Aldosterone treatment completely blocked this effect. These results demonstrate that aldosterone suppresses both activity and protein expression of hen colonic SGLT. Resalination either through decreased aldosterone or other factors may be able to activate SGLT activity independently of

increases in protein expression.
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:120402 CAPLUS
DOCUMENT NUMBER: 134:305166
TITLE: Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
AUTHOR(S): Arakawa, Kenji; Ishihara, Tomomi; Oku, Akira; Nawano, Masao; Ueta, Kiichiro; Kitamura, Kazuyuki; Matsumoto, Mamoru; Saito, Akira
CORPORATE SOURCE: Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, 335-8505, Japan
SOURCE: British Journal of Pharmacology (2001), 132(2), 578-586
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The therapeutic effects of an orally active inhibitor of Na+-glucose cotransporter (SGLT), T-1095 (a derivative of phlorizin; 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(6-O-methoxycarbonyl-β-D-glycopyranoside)) were examined in C57BL/KsJ-db/db mice, a genetic animal model of obese type 2 diabetes. The higher renal SGLT activity in db/db mice than normoglycemic C57BL/KsJ-db/ + m mice may support the rationale for using an SGLT inhibitor in the treatment regimen for type 2 diabetes. Both T-1095 and its metabolite, T-1095A, which had approx. 10 times more potency, effectively inhibited renal SGLT activity of these mice in vitro. Single oral administration of T-1095 (10, 30, 100 mg kg-1, p.o.) to db/db mice caused a dose-dependent reduction in blood glucose levels and a concomitant increase in glucose excretion into urine. In contrast, T-1095 only slightly affected blood glucose levels in db/ + m mice. Chronic administration of T-1095 (0.1% w w-1 pellet chow, for 12 wk) decreased blood glucose and Hb A1C levels, and improved glucose intolerance in db/db mice. The age-related decrease in plasma insulin levels was markedly inhibited and there was a 2.5 fold increase of insulin content in the pancreas of T-1095-treated db/db mice. Food consumption was not changed, while impaired body weight gain was ameliorated by T-1095 treatment. Both the development of albuminuria and the expansion of glomerular mesangial area in db/db mice were significantly suppressed by chronic T-1095 treatment, indicating the prevention of the progression of diabetic nephropathy. These results demonstrate that the SGLT inhibitor T-1095 is able to improve the metabolic abnormalities and inhibit the development of diabetic complications in db/db mice. Thus, T-1095 can be used for therapy of type 2 diabetic patients.
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:863196 CAPLUS
DOCUMENT NUMBER: 134:157426
TITLE: Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats
AUTHOR(S): Oku, Akira; Ueta, Kiichiro; Arakawa, Kenji; Kano-Ishihara, Tomomi; Matsumoto, Mamoru; Adachi, Tetsuya; Yasuda, Koichiro; Tsuda, Kinsuke; Saito, Akira
CORPORATE SOURCE: Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., Saitama, 335-8505, Japan
SOURCE: Biological & Pharmaceutical Bulletin (2000), 23(12), 1434-1437

CODEN: BPBLEO; ISSN: 0918-6158
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
AB T-1095, a derivative of phlorizin, is an orally active inhibitor of Na+-glucose cotransporter (SGLT). We investigated the acute antihyperglycemic effect of T-1095 in streptozotocin-induced diabetic rats (STZ rats). T-1095 and its metabolite T-1095A inhibited the SGLT activity in brush border membranes prepared from kidneys of both normal and STZ rats, but the latter agent was approx. 10 times more potent than the former. Single oral administration of T-1095 (30-100 mg/kg) dose-dependently induced glycosuria in normal rats. The fed glucose levels in STZ rats were dose-dependently suppressed by single oral administration of T-1095 (3-100 mg/kg), whereas there was only marginal hypoglycemic effect in normal rats. Since there was no effect on blood glucose in nephrectomized STZ rats, inhibition of renal glucose reabsorption rather than intestinal glucose absorption mainly contributes to the antihyperglycemic effect of T-1095. In conclusion, T-1095 is the first orally active agent which has an acute antihyperglycemic action in the absence of endogenous insulin secretion with a low risk of hypoglycemia and has therapeutic potential for treatment of diabetes mellitus.
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.75	16.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

FILE 'STNGUIDE' ENTERED AT 11:27:00 ON 08 JUN 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> d his

(FILE 'HOME' ENTERED AT 11:25:09 ON 08 JUN 2007)

FILE 'CAPLUS' ENTERED AT 11:25:30 ON 08 JUN 2007
L1 4 S SGLT ACTIVITY?

FILE 'STNGUIDE' ENTERED AT 11:27:00 ON 08 JUN 2007

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	17.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.12

STN INTERNATIONAL LOGOFF AT 11:28:30 ON 08 JUN 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:29:55 ON 08 JUN 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 09:30:53 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2007 HIGHEST RN 936802-99-2
DICTIONARY FILE UPDATES: 7 JUN 2007 HIGHEST RN 936802-99-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591757a.str





chain nodes :
12 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
7-12 12-13 16-19 17-20 18-21
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 7-12 8-9 12-13 13-14 13-18 14-15
15-16 16-17 16-19 17-18 17-20 18-21
isolated ring systems :
containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :

```
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  12:CLASS
13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:CLASS  20:CLASS  21:CLASS



L1      STRUCTURE UPLOADED

=> d l`
L1 HAS NO ANSWERS
'L` ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
          data.  (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
          data.
SDA ----- All Structure DAta (image, attributes, connection table and
          map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:n
'N' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
          data.  (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
          data.
SDA ----- All Structure DAta (image, attributes, connection table and
          map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:0
'0' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
          data.  (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
          data.
SDA ----- All Structure DAta (image, attributes, connection table and
          map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:nos
L1              STR


=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 C,N

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:32:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       20 TO ITERATE

100.0% PROCESSED       20 ITERATIONS                          4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          132 TO      668
PROJECTED ANSWERS:               4 TO      200

L2             4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:32:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      372 TO ITERATE

100.0% PROCESSED      372 ITERATIONS                         88 ANSWERS
SEARCH TIME: 00.00.01

L3            88 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              173.45     173.87

FILE 'CAPLUS' ENTERED AT 09:32:59 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 8 Jun 2007 VOL 146 ISS 25
FILE LAST UPDATED: 7 Jun 2007 (20070607/ED)

=> s l3 full
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1004761 CAPLUS
DOCUMENT NUMBER: 143:306497
TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotaka; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1950389	A	20070418	CN 2005-80014287	20050303
PRIORITY APPLN. INFO.:			JP 2004-61426 A	20040304
			WO 2005-JP4145 W	20050303

OTHER SOURCE(S): MARPAT 143:306497

GI



AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) [R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxycarbonyl-C1-6 alkyl, CO2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2] are prepared These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.

IT 864844-68-8P 864846-28-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864844-68-8 CAPLUS

CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864846-28-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 864844-07-5P 864844-08-6P 864844-09-7P
864844-14-4P 864844-15-5P 864844-16-6P
864844-17-7P 864844-18-8P 864844-19-9P
864844-20-2P 864844-22-4P 864844-23-5P
864844-25-7P 864844-27-9P 864844-28-0P
864844-29-1P 864844-30-4P 864844-32-6P
864844-34-8P 864844-36-0P 864844-37-1P
864844-38-2P 864844-39-3P 864844-41-7P

864844-42-8P 864844-43-9P 864844-44-0P
864844-45-1P 864844-46-2P 864844-47-3P
864844-48-4P 864844-49-5P 864844-50-8P
864844-51-9P 864844-52-0P 864844-53-1P
864844-54-2P 864844-55-3P 864844-56-4P
864844-58-6P 864844-62-2P 864844-63-3P
864844-69-9P 864844-70-2P 864844-71-3P
864844-72-4P 864844-73-5P 864844-74-6P
864844-75-7P 864844-76-8P 864844-77-9P
864844-78-0P 864844-79-1P 864844-80-4P
864844-81-5P 864844-82-6P 864844-83-7P
864844-84-8P 864844-85-9P 864844-86-0P
864844-87-1P 864844-88-2P 864844-89-3P
864844-90-6P 864844-95-1P 864844-96-2P
864844-97-3P 864844-98-4P 864844-99-5P
864845-00-1P 864845-01-2P 864845-02-3P
864845-04-5P 864845-05-6P 864845-06-7P
864845-07-8P 864845-08-9P 864845-09-0P
864845-10-3P 864845-12-5P 864845-13-6P
864845-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864844-07-5 CAPLUS
CN β-D-Glucopyranoside, 4-(2-phenylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-08-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxy-3-methylphenyl)ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-09-7 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-pyridinyl)ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-14-4 CAPLUS
CN β-D-Glucopyranoside, 4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-15-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-16-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetic acid, 3-(β-D-glucopyranosyloxy)-4-[2-[4-(phenylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-17-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-18-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-19-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-20-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-22-4 CAPLUS
CN Propanamide, 2-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl]phenoxy]propyl]amino]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-23-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 864844-25-7 CAPLUS
CN Benzenebutanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl]-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-27-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-28-0 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(2-methoxyethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-29-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-30-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-32-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-butanamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-34-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(3-hydroxypropyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-36-0 CAPLUS
CN β-D-Glucopyranoside, 1-(3-aminopropyl)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-37-1 CAPLUS
CN Acetamide, 2-amino-N-[3-[3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-1-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-38-2 CAPLUS
CN β-D-Glucopyranoside, 1-[2-(dimethylamino)ethyl]-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-39-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 864844-41-7 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-42-8 CAPLUS
CN β-D-Glucopyranoside, 1-ethyl-4-[2-(4-methoxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-43-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-44-0 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-45-1 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-46-2 CAPLUS
CN Glycine, N-[[3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-47-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-48-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(3-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-49-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-50-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(3-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-51-9 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-[2-(4-methylphenyl)ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-52-0 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-[2-(3-methylphenyl)ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-53-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-54-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-hydroxyphenyl)ethynyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-55-3 CAPLUS
CN β-D-Glucopyranoside, 4-[(3-hydroxyphenyl)ethynyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-56-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxy-3-methylphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-58-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-62-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-(3-hydroxypropoxy)phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-63-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-hydroxypropoxy)phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-69-9 CAPLUS
CN Propanamide, 3-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-70-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-71-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-72-4 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-73-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-74-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[3-(dimethylamino)propyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-75-7 CAPLUS
CN Propanamide, 2-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]phenoxy]propyl]amino]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-76-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 864844-77-9 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-78-0 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 864844-79-1 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-80-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[2-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-81-5 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-82-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[3-[2-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-83-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-84-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[3-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-85-9 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-86-0 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-87-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-88-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(2-aminoethoxy)phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-89-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-90-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-[4-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 864844-95-1 CAPLUS
CN Benzenebutanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-96-2 CAPLUS
CN Benzenepentanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-97-3 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-98-4 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-99-5 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-00-1 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-01-2 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-02-3 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-04-5 CAPLUS
CN Benzenepropanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-05-6 CAPLUS
CN Benzenepropanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-06-7 CAPLUS
CN Benzenepropanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-07-8 CAPLUS
CN Benzenepropanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-08-9 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-09-0 CAPLUS
CN Benzenebutanamide, N-[2-(4-ethyl-1-piperazinyl)-1,1-dimethyl-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-10-3 CAPLUS
CN 1H-Indazole-1-acetamide, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-12-5 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1H-indazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-13-6 CAPLUS
CN 1H-Indazole-1-acetamide, 4-[2-[4-[4-[[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]amino]-4-oxobutyl]phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-14-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 864845-32-9P 864845-35-2P 864845-66-9P
864845-67-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864845-32-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-carboxamide, 3-(β-D-glucopyranosyloxy)-4-[2-[4-(phenylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-35-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(phenylmethoxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-66-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-azidopropoxy)phenyl]ethyl]-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-67-0 CAPLUS
CN 1H-Indazole-1-acetamide, 4-[2-[4-(3-azidopropoxy)phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:29:55 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 09:30:53 ON 08 JUN 2007
L1 STRUCTURE UPLOADED
L2 4 S L1
L3 88 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:32:59 ON 08 JUN 2007
L4 1 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.21	180.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

STN INTERNATIONAL LOGOFF AT 09:34:26 ON 08 JUN 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:24:54 ON 08 JUN 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 09:26:25 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2007 HIGHEST RN 936802-99-2
DICTIONARY FILE UPDATES: 7 JUN 2007 HIGHEST RN 936802-99-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591757.str





chain nodes :
12 19 20 21 22 24
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
6-22 7-12 12-13 16-19 17-20 18-21 22-24
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 6-22 7-8 7-12 8-9 12-13 13-14 13-18
14-15 15-16 16-17 16-19 17-18 17-20 18-21 22-24
isolated ring systems :
containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 24:Atom

Generic attributes :
24:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:27:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:27:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 190 TO ITERATE

100.0% PROCESSED 190 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

```
L3             1 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     172.73

FILE 'CAPLUS' ENTERED AT 09:27:13 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 8 Jun 2007  VOL 146 ISS 25
FILE LAST UPDATED: 7 Jun 2007  (20070607/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 ful
L4             1 L3

=> d ibib abs hitstr tot

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:1004761  CAPLUS
DOCUMENT NUMBER:          143:306497
TITLE:                    Preparation of nitrogenous fused-ring glycoside
                          derivatives as inhibitors of human sodium-dependent
                          glucose transporter (SGLT)
INVENTOR(S):              Fushimi, Nobuhiko; Teranishi, Hirotaka; Shimizu,
                          Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji,
                          Masayuki
PATENT ASSIGNEE(S):       Kissei Pharmaceutical Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 169 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005085267         A1    20050915    WO 2005-JP4145          20050303
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
```

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1950389	A	20070418	CN 2005-80014287	20050303
PRIORITY APPLN. INFO.:			JP 2004-61426	A 20040304
			WO 2005-JP4145	W 20050303

OTHER SOURCE(S): MARPAT 143:306497
GI



AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) [R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxycarbonyl-C1-6 alkyl, CO2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2] are prepared These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.

IT 864845-14-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864845-14-7 CAPLUS

CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:24:54 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 09:26:25 ON 08 JUN 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:27:13 ON 08 JUN 2007
L4 1 S L3 FUL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.21	178.94
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

STN INTERNATIONAL LOGOFF AT 09:28:12 ON 08 JUN 2007